Pharma: Clinic Roundup
Thursday, August 1, 2013
Boehringer Ingelheim Pharmaceuticals GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, jointly announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) tablets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.